Lupin Drug Patent Portfolio
Lupin owns 5 orange book drugs protected by 38 US patents with Antara (Micronized) having the least patent protection, holding only 4 patents. And Brovana with maximum patent protection, holding 13 patents. Given below is the list of Lupin's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11684607 | Secnidazole for use in the treatment of bacterial vaginosis | 16 Sep, 2035 | Active |
| US10335390 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US10682338 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US10849884 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US10857133 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US11000507 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US11000508 | Secnidazole for use in the treatment of trichomoniasis | 04 Sep, 2035 | Active |
| US11020377 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US11324721 | Secnidazole for use in the treatment of trichomoniasis | 04 Sep, 2035 | Active |
| US11602522 | Secnidazole for use in the treatment of sexually transmitted infection | 04 Sep, 2035 | Active |
| US9314447 | Reduced dose pharmaceutical compositions of fenofibrate | 31 May, 2033 | Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8026281 | Treating metabolic syndrome with fenofibrate | 22 Apr, 2025 | Active |
| US7256310 | Levalbuterol salt | 08 Oct, 2024 | Active |
| US8765153 | Levalbuterol salt | 08 Dec, 2023 | Expired |
| US6472563 | Formoterol tartrate process and polymorph | 09 Nov, 2021 | Expired |
| US6720453 | Formoterol tartrate polymorph | 09 Nov, 2021 | Expired |
| US7145036 | Formoterol tartrate polymorph | 09 Nov, 2021 | Expired |
| US8110706 | Formoterol tartrate process and polymorph | 09 Nov, 2021 | Expired |
| US6667344 | Bronchodilating compositions and methods | 22 Jun, 2021 | Expired |
| US6814953 | Bronchodilating compositions and methods | 22 Jun, 2021 | Expired |
| US7348362 | Bronchodilating β-agonist compositions and methods | 22 Jun, 2021 | Expired |
| US7462645 | Bronchodilating beta-agonist compositions and methods | 22 Jun, 2021 | Expired |
| US7465756 | Bronchodilating beta-agonist compositions and methods | 22 Jun, 2021 | Expired |
| US7473710 | Bronchodilating beta-agonist compositions and methods | 22 Jun, 2021 | Expired |
| US7541385 | Bronchodilating β-agonist compositions and methods | 22 Jun, 2021 | Expired |
| US7101574 | Pharmaceutical composition containing fenofibrate and the preparation method | 20 Aug, 2020 | Expired |
| US7863331 | Pharmaceutical composition containing fenofibrate and method for the preparation thereof | 08 Aug, 2020 | Expired |
| US6040344 | Formoterol process | 12 Nov, 2016 | Expired |
| US5836299 | Seals for use in an aerosol delivery device | 17 Nov, 2015 | Expired |
| US5605674 | Medicinal aerosol formulations | 25 Feb, 2014 | Expired |
| US5547994 | Method for treating asthma using optically pure R(-) albuterol | 20 Aug, 2013 | Expired |
| US6589508 | Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol | 03 Apr, 2013 | Expired |
| US5362755 | Method for treating asthma using optically pure (R)-albuterol | 25 Mar, 2013 | Expired |
Latest Legal Activities on Lupin's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Lupin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US11000508 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US11000507 |
|
Expire Patent
Critical
| 11 Mar, 2024 | US8110706 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Dec, 2023 | US10857133 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Dec, 2023 | US10849884 |
|
Maintenance Fee Reminder Mailed
Critical
| 25 Sep, 2023 | US8110706 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jun, 2023 | US10682338 |
|
Email Notification
Critical
| 27 Jun, 2023 | US11684607 |
| Mail Patent eGrant Notification | 27 Jun, 2023 | US11684607 |
|
Recordation of Patent Grant Mailed
Critical
| 27 Jun, 2023 | US11684607 |
| Patent eGrant Notification | 27 Jun, 2023 | US11684607 |
|
Electronic Review
Critical
| 27 Jun, 2023 | US11684607 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 27 Jun, 2023 | US11684607 |
| Recordation of Patent eGrant | 27 Jun, 2023 | US11684607 |
|
Electronic Review
Critical
| 08 Jun, 2023 | US11684607 |
Lupin Drug Patents' Oppositions Filed in EPO
Lupin drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 16, 2011, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP06110646A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP06110646A | Nov, 2011 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
Lupin's Family Patents
Lupin drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 32.2% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Lupin Drug List
Given below is the complete list of Lupin's drugs and the patents protecting them.
1. Antara (micronized)
Antara (micronized) is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9314447 | Reduced dose pharmaceutical compositions of fenofibrate |
31 May, 2033
(8 years from now)
| Active |
| US8026281 | Treating metabolic syndrome with fenofibrate |
22 Apr, 2025
(6 months from now)
| Active |
| US7101574 | Pharmaceutical composition containing fenofibrate and the preparation method |
20 Aug, 2020
(4 years ago)
| Expired |
| US7863331 | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
08 Aug, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Antara (micronized)'s drug page
2. Brovana
Brovana is protected by 13 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6472563 | Formoterol tartrate process and polymorph |
09 Nov, 2021
(2 years ago)
| Expired |
| US6720453 | Formoterol tartrate polymorph |
09 Nov, 2021
(2 years ago)
| Expired |
| US7145036 | Formoterol tartrate polymorph |
09 Nov, 2021
(2 years ago)
| Expired |
| US8110706 | Formoterol tartrate process and polymorph |
09 Nov, 2021
(2 years ago)
| Expired |
| US6667344 | Bronchodilating compositions and methods |
22 Jun, 2021
(3 years ago)
| Expired |
| US6814953 | Bronchodilating compositions and methods |
22 Jun, 2021
(3 years ago)
| Expired |
| US7348362 | Bronchodilating β-agonist compositions and methods |
22 Jun, 2021
(3 years ago)
| Expired |
| US7462645 | Bronchodilating beta-agonist compositions and methods |
22 Jun, 2021
(3 years ago)
| Expired |
| US7465756 | Bronchodilating beta-agonist compositions and methods |
22 Jun, 2021
(3 years ago)
| Expired |
| US7473710 | Bronchodilating beta-agonist compositions and methods |
22 Jun, 2021
(3 years ago)
| Expired |
| US7541385 | Bronchodilating β-agonist compositions and methods |
22 Jun, 2021
(3 years ago)
| Expired |
| US6040344 | Formoterol process |
12 Nov, 2016
(7 years ago)
| Expired |
| US6589508 | Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol |
03 Apr, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brovana's drug page
3. Sesquient
Sesquient is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(8 years from now)
| Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sesquient's drug page
4. Solosec
Solosec is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11684607 | Secnidazole for use in the treatment of bacterial vaginosis |
16 Sep, 2035
(10 years from now)
| Active |
| US10335390 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US10682338 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US10849884 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US10857133 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US11000507 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US11000508 | Secnidazole for use in the treatment of trichomoniasis |
04 Sep, 2035
(10 years from now)
| Active |
| US11020377 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US11324721 | Secnidazole for use in the treatment of trichomoniasis |
04 Sep, 2035
(10 years from now)
| Active |
| US11602522 | Secnidazole for use in the treatment of sexually transmitted infection |
04 Sep, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Solosec's drug page
5. Xopenex Hfa
Xopenex Hfa is protected by 6 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7256310 | Levalbuterol salt |
08 Oct, 2024
(2 days from now)
| Active |
| US8765153 | Levalbuterol salt |
08 Dec, 2023
(9 months ago)
| Expired |
| US5836299 | Seals for use in an aerosol delivery device |
17 Nov, 2015
(8 years ago)
| Expired |
| US5605674 | Medicinal aerosol formulations |
25 Feb, 2014
(10 years ago)
| Expired |
| US5547994 | Method for treating asthma using optically pure R(-) albuterol |
20 Aug, 2013
(11 years ago)
| Expired |
| US5362755 | Method for treating asthma using optically pure (R)-albuterol |
25 Mar, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xopenex Hfa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List